HUTCHMED (China) Limited (NASDAQ:HCM) Stake Cut by Bellevue Group AG

Bellevue Group AG decreased its holdings in shares of HUTCHMED (China) Limited (NASDAQ:HCM) by 97.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,015 shares of the company’s stock after selling 1,125,142 shares during the period. Bellevue Group AG’s holdings in HUTCHMED were worth $469,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of HCM. M&G PLC lifted its holdings in shares of HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company’s stock worth $5,345,000 after purchasing an additional 132,333 shares during the last quarter. Renaissance Technologies LLC increased its position in HUTCHMED by 74.8% in the second quarter. Renaissance Technologies LLC now owns 131,300 shares of the company’s stock worth $2,248,000 after buying an additional 56,200 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in HUTCHMED by 99.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock worth $952,000 after buying an additional 24,245 shares during the period. Crossmark Global Holdings Inc. bought a new stake in HUTCHMED in the third quarter valued at $328,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of HUTCHMED during the second quarter valued at $279,000. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Price Performance

Shares of NASDAQ HCM opened at $16.95 on Monday. HUTCHMED has a 12-month low of $11.93 and a 12-month high of $21.92. The stock has a 50 day simple moving average of $18.86 and a 200-day simple moving average of $18.44. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07.

Analyst Ratings Changes

Separately, StockNews.com cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Monday, November 18th.

HUTCHMED Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.